This paper compared the detection of Epstein-Barr virus (EBV) in nasal and nasopharyngeal swab specimens from patients with nasopharyngeal carcinoma. Differences due to patient age and gender were also investigated.
Evaluation of nasal and nasopharyngeal swab collection for the detection of Epstein-Barr virus in nasopharyngeal carcinoma.
Coghill AE, Wang CP, Verkuijilen SAWM, Yu KJ, Hsu WL, Middeldorp JM, Hildesheim A
Purpose
Conclusion
EBV DNA was detected in all nasopharyngeal swabs and levels were above the positivity threshold (1666 EBV copies per swab) in 88.2% patients. In contrast, EBV DNA was detected in only 50% of nasal swabs and above the positivity threshold in only 11.8% of patients. The correlation was modest between EBV DNA levels among the 17 patients with detectable EBV DNA in both their nasopharyngeal and nasal swabs. Average log EBV DNA levels were comparable between males and females but increased with patient age.
Studies (1)
Purpose
This study compared the detection of Epstein-Barr virus in nasal and nasopharyngeal swab specimens from patients with nasopharyngeal carcinoma. Differences due to patient age and gender were also investigated. A nasal swab and nasopharyngeal swab specimen were each collected from both the left and right nasal cavity (four swabs total) from 34 patients with histologically confirmed nasopharyngeal carcinoma. Nasal swabs were collected from the anterior third of the inferior turbinate and nasopharyngeal swabs were collected from the nasopharyngeal mucosa through the inferior meatus along the nasal floor. Swabs were rotated at least twice before removal, placed in a cryovial containing specimen transport medium buffer, and frozen in liquid nitrogen. DNA was extracted by silica-based nucleic acid extraction. EBV DNA viral load was determined by a real-time qRT-PCR targeting a 213 bp region of the BKRF1 gene encoding Epstein-Barr nuclear antigen-1.
Summary of Findings
EBV DNA was detected in all nasopharyngeal swabs and levels were above the positivity threshold (1666 EBV copies per swab) in 88.2% patients (30/34). In contrast, EBV DNA was detected in only 50% of nasal swabs and above the positivity threshold in only 11.8% of patients (4/34). The average log EBV DNA level was >3-fold lower in nasal swabs compared to nasopharyngeal swabs (P<0.001). The correlation was modest between EBV DNA levels among the 17 patients with detectable EBV DNA in both their nasopharyngeal and nasal swabs (Spearman correlation=0.69, P<0.01). Average log EBV DNA levels in nasopharyngeal swabs were non-significantly higher in patients with EBV DNA detectable in nasal swabs compared to patients with no detectable EBV in the nasal swab (12.2 versus 10.7, P=0.11). Average log EBV DNA levels were comparable between males and females (P=0.92) but increased with patient age (10.4 at <40 years, 11.0 at 40-50 years, 11.4 at 51-59 years, and 13.5 for patients 60+ years; P-trend=0.04).
Biospecimens
CellNasal cavityCellNasopharynxPreservation Types
FrozenDiagnoses
NeoplasticCarcinomaPneumonia/Respiratory InfectionPlatforms
RNAReal-time qRT-PCRPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Patient age 40-50 years51-59 years60+ years<40 yearsPreaquisition Patient gender FemaleMaleReal-time qRT-PCR Specific Targeted nucleic acid 213 bp region of the BKRF1 gene encoding Epstein-Barr nuclear antigen-1